1. Severe hypertrophic cardiomyopathy in a patient with atypical Anderson-Fabry disease
- Author
-
Daniele Masarone, Martina Caiazza, Giuseppe Limongelli, Paolo Colomba, Annapaola Cirillo, Santo Dellegrottaglie, Antonio Pisani, Paolo Calabrò, Marta Rubino, Perry M. Elliott, Giuseppe Pacileo, Giovanni Duro, Masarone, Daniele, Duro, Giovanni, Dellegrottaglie, Santo, Colomba, Paolo, Rubino, Marta, Cirillo, Annapaola, Pisani, Antonio, Caiazza, Martina, Elliott, Perry Mark, Calabro', Paolo, Pacileo, Giuseppe, Limongelli, Giuseppe, and Calabrò, Paolo
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Magnetic Resonance Imaging, Cine ,Disease ,Anderson-Fabry disease ,030204 cardiovascular system & hematology ,Left ventricular hypertrophy ,Multimodal Imaging ,Risk Assessment ,Severity of Illness Index ,cardiac magnetic resonance ,sudden cardiac death ,Sudden cardiac death ,Electrocardiography ,03 medical and health sciences ,Rare Diseases ,0302 clinical medicine ,enzymatic replacement therapy ,Internal medicine ,Severity of illness ,medicine ,Humans ,echocardiography ,030212 general & internal medicine ,cardiomyopathie ,medicine.diagnostic_test ,business.industry ,Hypertrophic cardiomyopathy ,Cardiomyopathy, Hypertrophic ,Middle Aged ,medicine.disease ,Implantable cardioverter-defibrillator ,Fabry disease ,Defibrillators, Implantable ,Isoenzymes ,Death, Sudden, Cardiac ,Treatment Outcome ,alpha-Galactosidase ,Cardiology ,Fabry Disease ,Molecular Medicine ,Cardiology and Cardiovascular Medicine ,business ,Follow-Up Studies - Abstract
Aim: Anderson-Fabry disease (AFD) is a hereditary disorder caused by a deficiency in the lysosomal enzyme α-galactosidase A which causes dysfunctions in multiple organ systems. Cardiac manifestation includes left ventricular hypertrophy, thickening of the valves, conduction disturbances and in the late phase, extensive areas of myocardial fibrosis with increased risk of sudden cardiac death. Case example: A case of AFD with exclusive cardiac involvement is described. During follow-up, due to the high risk of life-threatening arrhythmic events, implantation of an implantable cardioverter defibrillator is performed. Conclusion: AFD patients with advanced cardiac disease might represent a subgroup of patients who may require an implantable cardioverter defibrillator for primary prevention of sudden cardiac death.
- Published
- 2017
- Full Text
- View/download PDF